Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation by Carrasco, Esther et al.
Lowered cortistatin expression is an early event in the human
diabetic retina and is associated with apoptosis and glial activation
Esther Carrasco,1,2 Cristina Hernández,1,2 Inés de Torres,3 Jaume Farrés,4 Rafael Simó1,2
(The first two authors contributed equally to this work.)
1Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM) from Instituto de
Salut Carlos III (ISCIII), Barcelona, Spain; 2Diabetes Research Unit, Institut de Recerca Hospital Universitari Vall d’Hebron,
Universitat Autònoma de Barcelona, Barcelona, Spain; 3Pathology Department, Institut de Recerca Hospital Universitari Vall
d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain; 4Department of Biochemistry and Molecular Biology, Universitat
Autònoma de Barcelona, Barcelona, Spain
Purpose: Cortistatin (CST), a neuropeptide with strong structural and functional similarities to somatostatin, is abundant
in the vitreous fluid, and it is decreased in patients with proliferative diabetic retinopathy. The aims of the present study
were to explore whether the retina produces CST, and to compare its expression between diabetic and nondiabetic donors.
Retinal neurodegeneration was assessed by measuring glial fibrilar acidic protein (GFAP) by confocal laser microscopy
and counting the apoptotic TUNEL positive cells in which nuclear fragmentation as well as condensation were present.
Methods: Human postmortem eyes (10) from five diabetic donors were compared with 10 eyes from five nondiabetic
donors, matched by age. CST mRNA (RT–PCR) and CST (confocal laser microscopy) were measured separately in both
the neuroretina and retinal pigment epithelium (RPE). Retinal neurodegeneration was assessed by measuring glial fibrillar
acidic protein (GFAP) by confocal laser microscopy and counting the apoptotic cells by TUNEL.
Results: CST was found to be produced by the human retina, and higher levels of CST mRNA were found in RPE than
in the neuroretina. CST mRNA levels in diabetic donors were significantly lower in both the RPE (p=0.001) and the
neuroretina (p=0.03) in comparison with nondiabetic donors. CST immunofluorescence was in agreement with mRNA
expression, but the differences were only significant when comparing neuroretinas (p=0.03). Increased GFAP and a higher
degree of apoptosis were observed in diabetic retinas in comparison with nondiabetic retinas. These changes were inversely
related with CST levels.
Conclusions: CST is expressed in the human retina. There is more CST in the RPE than in the neuroretina. A lower
expression of CST exists in diabetic retinas and it is associated with retinal neurodegeneration.
Proliferative  diabetic  retinopathy  (PDR)  remains  the
leading cause of blindness among adults aged <40 years in the
developed countries [1]. The balance between the angiogenic
and  antiangiogenic  factors  is  crucial  in  determining  the
progression  of  PDR.  We  previously  demonstrated  that
somatostatin (SST) concentration is higher in the vitreous
fluid than in plasma in nondiabetic subjects [2]. In addition, a
significantly lower intravitreous concentration of SST has
been detected in PDR patients [2] and patients with diabetic
macular edema [3] in comparison with nondiabetic control
subjects; SST-28 was the main molecular variant accounting
for this deficit [4]. Furthermore, we have found significantly
lower SST mRNA expression in retinas from diabetic donors
in comparison with nondiabetic donors [5]. These findings
suggest both that SST could be added to the list of natural
angiogenic inhibitors that exist in the vitreous fluid and that a
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deficit  of  intravitreal  SST  could  be  involved  in  retinal
neovascularization.
Cortistatin (CST) is a neuropeptide identified by Lecea
et al. [6] that has a strong structural similarity to SST. CST
shares 11 of 14 residues with SST, including those that are
essential  for  binding  to  the  five  SST  receptors  [7].  As  a
consequence, it has similar pharmacological and functional
properties to SST, including depression of neuronal activity
[7], and an inhibitory effect on growth hormone, prolactin,
and  insulin  secretion  [8].  Despite  many  similar  functions
between these two neuropeptides, SST and CST are products
of different genes. CST-17 and CST-29 are the two main CST
molecular variants cleaved from the human prepro-CST [9].
In initial studies, expression of CST has only been described
in  the  cerebral  cortex  [6],  but  further  studies  have
demonstrated expression of CST in several peripheral tissues
[10,11]. Indeed, we demonstrated that CST levels were higher
in the vitreous fluid than in the plasma and we found no
relationship between vitreous and plasma concentrations. In
addition, lower intravitreous levels of CST were detected in
PDR patients than in nondiabetic controls [4]. These findings
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1496suggest that CST is intraocularly synthesized, but to the best
of  our  knowledge  there  is  no  information  regarding  CST
expression in the retina.
The aim of the present study was to investigate CST
mRNA  and  protein  levels  in  retinas  from  diabetic  and
nondiabetic  donors.  Moreover,  to  gain  insight  into  the
mechanisms  responsible  for  the  decreased  CST
concentrations in the vitreous fluid of diabetic patients, we
assessed the relationship between retinal CST expression and
retinal neurodegeneration. This was assessed by measuring
glial  fibrilar  acidic  protein  (GFAP)  by  confocal  laser
microscopy  and  counting  TUNEL  positive  cells  in  which
nuclear fragmentation and condensation were present.
METHODS
Human retinas: Human postmortem eyes (10) were obtained
from five diabetic donors (64.5±8.3 years). Diabetic donors
had  no  history  of  renal  failure  or  cardiovascular  events.
Ophthalmic examinations performed two years before death
revealed  diabetic  donors  to  be  free  of  fundoscopic
abnormalities.  Eye  cups  obtained  from  five  nondiabetic
donors (10 cups in total), matched by age (66.2±6.4 years),
were used as the control group. Nondiabetic donors had no
history of renal failure or cardiovascular events. However, we
can not confirm that these subjects had normal eye exams two
years  prior  to  death  because  they  were  not  periodically
screened as diabetic patients. Nevertheless, it should be noted
that these patients did not have diabetes or any significant
ocular disease. Therefore, although they potentially could had
some mild ocular abnormalities, these lesions were absolutely
unrelated to diabetes and, in consequence, they constituted a
good control group for the purpose of the study. The clinical
characteristics  and  the  causes  of  death  for  diabetic  and
nondiabetic donors are shown in Table 1.
The  time  period  from  death  to  eye  enucleation  was
3.7±1.6 h. After enucleation, one eye cup from each donor
was snap frozen in liquid nitrogen and stored at –80° until
assayed for mRNA analysis. The other eye cup was fixed in
4%  paraformaldehyde  and  embedded  in  paraffin  for  the
immunohystochemical study.
All  ocular  tissues  were  used  in  accordance  with
applicable  laws  and  conformed  with  the  Declaration  of
Helsinki for research involving human tissue. In addition, this
study was approved by the ethics committee of our hospital.
mRNA isolation and cDNA synthesis: Neuroretina and RPE
were harvested during microscopic dissection of isolated eye
cups from donors. The neuroretina and RPE from each eye
were ground to powder in a mortar resting on dry ice. Poly A
+ mRNA from tissue samples was isolated using Dynabeads
oligo  (dT)25  (Invitrogen,  Eugene,  Oregon).  mRNA
concentration  was  determined  by  spectrophotometric
measures at 260 and 280 nm. Next, 200 ng aliquots of poly A
+ mRNA were reverse transcribed using the Cloned AMV
First-Strand cDNA synthesis Kit (Invitrogen) following the
manufacturer’s  protocol  for  oligo  (dT)20  priming.  The
resulting cDNA was then used in both semiquantitative and
real-time PCR reactions.
Semiquantitative  RT–PCR:  Expression  of  mRNA  was
evaluated by semiquantitative RT–PCR using 2 µl of first
strand  cDNA  as  template  and  gene  specific  primers.
Amplification of the cDNA samples with  β-actin primers
TABLE 1. CLINICAL CHARACTERISTICS AND CAUSES OF DEATH OF DIABETIC AND NONDIABETIC DONORS.
 
Diabetic
donors
n=5
Nondiabetic
Donors
n=5 p
Age (years) 64.5±8.3 66.2±6.4 n.s.
Gender (Male/Female) 4/1 4/1 n.s.
Type of diabetes (type 1/type 2) 0/5 -
Diabetes duration (years) 6.7±4.9 -
HbA1c (%) 7.4±0.5 -
Diabetes treatment   -
- diet only 2
- oral agents 3
- insulin 0
Cause of death  
- Cardiovascular disease 3 2
- Malignant neoplasm 1 3
- Traffic accident 1 0
As can be seen we did not find differences in age and gender between diabetic and nondiabetic patients included in the study.
The  following abbreviations are used in this table: glycosylated hemoglobin (HbA1c).
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In  parallel  with  cDNA  samples,  the  reactions  were  also
performed without DNA template to exclude contamination
of  the  PCR  reaction  mixtures.  cDNA  samples  known  to
contain CST mRNA were amplified as a positive control. To
insure  that  poly  A+  mRNA  was  not  contaminated  with
genomic  DNA,  we  performed  cDNA  reactions  without
reverse transcriptase and we amplified with each primer pair.
PCR was performed using Platinum Taq DNA polymerase
(Invitrogen). Sequences for primers used in semiquantitative
RT–PCR for CST and β-actin were designed in our laboratory
using published gene sequences and Primer Select software
(DNA Star Inc.3 Madison, WI), and are listed in Table 2. The
reaction mixture contained the following: 1X PCR buffer,
consisting of 20 mM Tris-HCl, pH 8.4, and 50 mM KCl; 100
µM dNTP; 1.5 mM MgCl2; 0.1 µM of each primer; 1 unit
Platinum Taq polymerase (Invitrogen); and 2 µl cDNA from
RT reaction. A brain cDNA sample was used as a positive
control. The brain sample was obtained from a donor (62 year
old man who died from stroke). After an initial denaturation
at 94 °C for 5 min, the samples were subjected to 40 cycles of
denaturation at 94 °C for 1 min, annealing at 63 °C for 1 min,
and extension at 68 °C for 1 min. After a final extension at
72 °C for 5 min, 10 µl aliquots of the resulting PCR products
were analyzed by electrophoresis on 2% agarose gels stained
with ethidium bromide.
Identities  of  the  products  were  confirmed  by  direct
sequencing using an ABI Prism 3100 Genetic Analyzer (PE
Applied Biosystems, Madrid, Spain).
Quantitative Real-Time PCR: Quantitative real-time PCR (Q-
RT–PCR) was performed using an ABI Prism 7000 Sequence
Detection  System  (Perkin-Elmer  Applied  Biosystems;
Madrid, Spain) according to the manufacturer’s protocol. The
reactions  were  performed  using  10  µl  of  2X  TaqMan
Universal PCR Master Mix (Applied Biosystems), 1 µl of 20X
Assay-on-Demand  TM  Gene  Expression  Assay  Mix
(Hs00174952_m1;  Applied  Biosystems),  which  includes
CST primers and probe, and 2 µl of cDNA template in a total
volume of 20 µl. Each sample was assayed in triplicate and
included a negative control in each experiment. Automatic
relative quantification of data from CST mRNA (arbitrary
units) was obtained by using an ABI Prism 7000 SDS software
(Applied Biosystems) and human β-actin as an endogenous
gene expression control (4333762T; Applied Biosystems).
CST immunofluorescence: Paraffinized eyes were serially cut
to 7 μm thickness. Sections were deparaffinized with xylene
and rehydrated in ethanol. Sections were then fixed and placed
in antigen-retrieval solution (Dako A/S, Glostrup, Denmark)
for 20 min at 95 °C. To eliminate autofluorescence of RPE
due to melanin and lipofuscin, we used a method described
elsewhere [12]. Briefly, slides were washed for 20 min in 0.2%
potassium permanganate and neutralized with 1% oxalic acid
until  the  brown  color  was  removed  (30-35  s),  and  then
immediately  rinsed  in  phosphate  buffered  saline  (PBS).
Sections were then incubated for 1 h with 1% BSA in 0.3%
Triton  X-100  in  PBS  to  block  unspecific  binding  of  the
antibodies and then incubated overnight at 4 °C with a specific
primary  antibody  to  human  CST-29  (Phoenix
Pharmaceuticals, Belmont, CA). Sections were washed before
being incubated with Alexa Fluor® 633 (Molecular Probes,
Eugene, OR) secondary antibody at room temperature for 1 h.
Slides were coverslipped with a drop of mounting medium
containing  DAPI  for  visualization  of  cell  nuclei  (Vector
Laboratories, Burlingame, CA).
Image  Acquisition—Images  were  acquired  with  a
confocal  laser  scanning  microscope  (FV1000,  Olympus.
Hamburg, Germany) using a 633 nm laser line for CST-29 and
a 405 nm laser for DAPI fluorophores. Each image was saved
at a resolution of 1024x1024 pixels.
Image  analysis—To  quantify  CST-29
immunofluorescence  in  RPE  and  the  neuroretina,  we
measured  the  total  fluorescence  intensity  values
corresponding  to  ten  field  frame  images  (40X  numerical
aperture [NA]: 0.9) of each retina sample. These results were
then  normalized,  taking  into  account  the  area  analyzed.
Calculations were made using specific software (Fluoview
ASW 1.4, Olympus, Hamburg, Germany).
Terminal  transferase  dUTP  nick-end  labeling:  Paraffin-
embedded eye sections (7 μm thickness) from diabetic and
nondiabetic  donors  were  processed  with  an  apoptosis-
detection  kit  (APO-BrdU  TUNEL  Assay  kit;  Molecular
Probes). TUNEL staining in the diabetic retina was compared
with that in the nondiabetic retina. For this purpose, each
retina was visually scanned with a high power lens (60X) that
covered 212x212 μm. The total number of TUNEL positive
cells was recorded for each retina in a masked fashion using
the values corresponding to 15 fields from 3 retinal sections
(five fields each). To avoid false-positive results, we have only
considered as apoptotic those TUNEL positive cells in which
TABLE 2. SEQUENCES OF PRIMERS USED IN SEMIQUANTITATIVE RT-PCR FOR CST AND β-ACTIN.
Primer name Nucleotide sequence (5′-3′) Amplicon size
CST-forward CTCCAGTCAGCCCACAAGAT 173 bp
CST-reverse CAAGCGAGGAAAGTCAGGAG
β-Actin-forward ATCGTGCGTGACATTAAGGAGAAGC 495 bp
β-Actin-reverse AGAAGCATTTGCGGTGGACGAT
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For this purpose we used interdifferential contrast (phase-
contrast  microscopy)  and  propidium-iodide
immunofluorescence.
Glial  fibrillar  acidic  protein  immunofluorescence:  Tissue
sections were incubated overnight at 4 °C with the primary
antibody  chicken  antihuman  GFAP  (1:1000;  Abcam,
Cambridge,  UK).  Sections  were  washed  before  being
incubated  with  Alexa  Fluor®  488  (Molecular  Probes)
secondary antibody for 1 h. GFAP immunofluorescence in the
neuroretina was quantified using a laser confocal microscopy,
and  the  units  represent  total  fluorescence  intensity  values
corresponding to ten field images (40X NA:0.9) of each retina
sample. GFAP immunofluorescence in the neuroretina was
quantified using a laser confocal scanning microscope. The
procedure was the same as mentioned above for CST.
Statistical  analysis:  Results  are  expressed  as  mean±  SD.
Comparisons  between  groups  (diabetic  and  nondiabetic
donors)  or  between  tissues  (RPE  and  neuroretina)  were
performed using the Student t test. Correlation analyses were
performed  by  using  Spearman’s  correlation  coefficient.
Levels of statistical significance were set at p<0.05.
RESULTS
Expression of CST in the human retina: comparison between
diabetic and nondiabetic retinas: β-actin mRNA expression
was similar in both the RPE and the neuroretina (p=0.12). In
addition,  no  differences  were  observed  in  β-actin  mRNA
expression between diabetic and nondiabetic retinas (p=0.73).
Thus, we have calculated CST mRNA gene expression after
normalizing with β-actin.
CST  mRNA  expression  in  diabetic  and  nondiabetic
retinas is compared in Figure 1. CST mRNA expression was
detected in the retinas from both nondiabetic and diabetic
donors, being higher in the RPE than in the neuroretina in all
cases. CST mRNA levels were significantly lower in both the
RPE and the neuroretina from diabetic donors in comparison
with nondiabetic donors (RPE: 0.37±0.24 versus 1.02±0.15;
p<0.001  and  neuroretina:  0.14±0.11  versus  0.26±0.08;
p=0.03).
Protein assessment in retina: comparison between diabetic
and nondiabetic retinas: Laser scanning confocal images of
CST  immunofluorescence  are  displayed  in  Figure  2.  We
detected a significantly higher content of CST in the RPE than
in  the  neuroretina  in  diabetic  donors  (8155±3459  versus
2386±114;  p=0.04)  but  not  in  nondiabetic  donors
(20113±12140 versus 8466±2256; p=0.2). The distribution of
CST  immunostaining  in  the  neuroretina  was  quite
homogeneous, but immunofluorescence of cells located in the
outer  nuclear  layer/photoreceptor  segment  appeared  to  be
more  intense.  CST  immunofluorescence  intensity  was
significantly lower in the neuroretina from diabetic donors in
comparison  with  nondiabetic  donors  (2386±114  versus
8466±2256; p=0.03). By contrast, we did not find statistical
differences in CST immunofluorescence between diabetic and
nondiabetic  donors  (81155±3459  versus  20113±12140;
p=0.2).
Effect of diabetes in retinal neurodegeneration: apoptosis and
glial activation: Diabetic retinas had a significantly higher
percentage  of  apoptotic  cells  than  the  age-matched
nondiabetic  retinas  both  in  the  RPE  (0.99±0.07%  versus
0.18±0.06%; p<0.0001) and in the neuroretina (0.36±0.05%
versus 0.08±0.04; p<0.001). Representative images of the
apoptotic  cells  detected  in  the  retinas  from  diabetic  and
nondiabetic donors are shown in Figure 3.
A higher ratio of apoptosis was found in RPE than in the
neuroretina.  This  was  true  for  both  diabetic  (0.99±0.07%
versus  0.36±0.05%;  p=0.03)  and  nondiabetic  retinas
(0.18±0.06% versus 0.08±0.04; p<0.01).
Figure 1. Expression of CST in the retinal pigment epithelia (RPE)
and in the neuroretina (N) of diabetic and nondiabetic donors. A:
Semiquantitative RT-PCR shows a higher CST expression in the
retina (RPE and N) from nondiabetic donors. Human β-actin was
used as internal control and, as can be seen, its signal intensity was
similar in the retina of diabetic and nondiabetic donors. B: This
shows real-time quantitative RT-PCR analysis of CST mRNA in
human  retinas.  The  bars  represent  the  mean±SD  of  the  values
obtained in the five diabetic and the five nondiabetic donors studied.
CST mRNA gene expression was calculated after normalizing with
β-actin. The following abbreviations are used in the figure: size
marker  (M);  positive  control,  human  brain  (C);  retinal  pigment
epithelium (RPE); and neuroretina (N).
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1499Neuroglial activation was demonstrated in diabetic eyes
by an increase of GFAP immunofluorescence in comparison
with  nondiabetic  neuroretinas  (6845±1964  versus
3238±1280; p<0.001; Figure 4). As previously described [5],
Müller cells acquire prominent GFAP immunofluorescence
throughout the extension of their processes in the diabetic
retina,  thus  replacing  the  normal  pattern  of  GFAP
immunostaining.
A significant inverse correlation was observed between
CST immunofluorescence and the percentage of apoptotic
cells  (r=-0.70;  p=0.01)  in  both  diabetic  and  nondiabetic
donors. Similarly, lower CST immunoreactivity was detected
in  those  retinas  with  higher  GFAP  expression  (r=-0.73;
p=0.03). Finally, a significant direct correlation was found
between  the  percentage  of  apoptotic  cells  and  GFAP
immunoflorescence (r=0.75; p=0.02). Taken together, these
findings strongly suggest that the higher the degree of retinal
neurodegeneration, the lower the rate of CST production.
DISCUSSION
In the present study we have demonstrated for the first time
that CST is expressed in the retina. In addition, we provide
Figure 2. A comparison of protein content of CST in the retina from
diabetic  and  nondiabetic  donors.  The  upper  panel  shows  a
comparison  of  CST-29  immunofluorescence  (red)  in  the  human
retina between representative samples from a non diabetic donor
(A) and a diabetic donor (B). The bar represents 20 μm. Lower panel:
quantification of CST-29 immunofluorescence in non-diabetic and
diabetic retinas. The following abbreviations are used in the figure:
retinal pigment epithelium (RPE); outer nuclear layer (ONL); inner
nuclear layer (INL); and ganglion cell layer (GLC).
evidence that CST mRNA expression is lower in diabetic
retinas  (both  in  the  neuroretina  and  the  RPE)  than  in
nondiabetic retinas. This finding could explain our previous
results regarding the deficit of intravitreous levels of CST in
patients  with  PDR  [4].  It  should  be  noted  that  diabetic
fundoscopic  abnormalities  were  not  detected  in  diabetic
donors in the two years preceding death, thus suggesting that
the lower CST expression detected in diabetic subjects is an
early  event  in  the  development  of  diabetic  retinopathy.
Recently, we have obtained similar results with SST [5].
The functional role of CST in retinal physiology remains
to  be  elucidated.  Since  CST  binds  all  five  cloned  SST
receptors, it could be speculated that it acts like SST in sharing
antiangiogenic  and  neuroprotective  effects  [1].  However,
CST also has properties which distinguish it from SST. In this
regard, it should be noted that CST, but not SST, has been
detected  in  various  human  immune  cells,  including
lymphocytes, monocytes, macrophages, and dendritic cells
[10,11].  Because  CST  levels  correlate  with  the  degree  of
inflammatory cell differentiation and activation [10,11], this
peptide  could  function  as  a  major  endogenous  regulatory
factor in the immune system. The superior potency of CST in
reducing inflammation as compared with SST and octreotide
might  reside  in  the  capacity  of  CST  to  activate  different
receptors and transduction pathways. This is supported by the
fact  that  the  SST  receptor  antagonist  cyclosomatostatin
completely reversed the antiinflammatory effect of SST and
octreotide in vitro, whereas only partially reversing the effect
of CST [12]. CST-29 has recently been shown to prevent
inflammation in rodent models for human diseases, raising
Figure 3. Representative images of apoptosis in the retina. Upper
panel:  nondiabetic  donor  (A:  propidium  iodide,  B:  TUNEL
immunofluorescence). Lower panel: diabetic donor (C: propidium
iodide,  D:  TUNEL  immunofluorescence).  The  following
abbreviations  are  used  in  the  figure:  retinal  pigment  epithelium
(RPE); outer nuclear layer (ONL); inner nuclear layer (INL); and
ganglion cell layer (GCL). The bar represents 20 μm.
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1500novel therapeutic properties for this neuropeptide [13]. In this
regard, it has been demonstrated that the therapeutic anti-
inflammatory effect of CST is mediated by decreasing the
local and systemic levels of a wide spectrum of inflammatory
mediators, including cytokines, chemokines, and acute phase
proteins [12,14]. Given that inflammation plays an important
role in the pathogenesis of diabetic retinopathy [15-21], the
low  levels  of  CST  detected  in  diabetic  patients  might
contribute to the enhancement of this pathogenic pathway.
Yan et al. [22] have shown that expression of CST and SST
and SST-receptors are all downregulated by TNF-alpha in
human  coronary  artery  endothelial  cells.  TNF-alpha  is  a
cytokine involved in the pathogenesis of diabetic retinopathy
[15,17,18,20] and, therefore, it could also be possible that the
lower levels of CST detected in diabetic patients were the
consequence rather than the cause of inflammation.
In the present study, CST retinal levels were inversely
associated with apoptosis and glial activation degree, two of
the characteristic features of retinal neurodegeneration [23,
24]. We have recently found similar results with SST [5].
Neurodegeneration is an important event in the pathogenesis
of  diabetic  retinopathy  and  it  has  been  involved  in  the
functional deficits in vision that first appear in diabetes even
before vascular abnormalities can be appreciated [25-27]. The
design of our study does not permit us to answer whether the
lower  CST  expression  in  diabetic  retinas  is  a  cause  or  a
Figure 4. A comparison of glial fibrillar acidic protein ( GFAP)
immunofluorescence between diabetic and nondiabetic donors. The
upper panel shows images of representative samples of retina from
a non-diabetic donor (A) and a diabetic donor (B). In the diabetic
retina,  the  endfeet  of  the  Müller  cells  showed  abundant  GFAP
immunofluorescence  (green),  and  the  radial  processed  stained
intensely throughout both the inner and the outer retina. The lower
panel shows the quantification of GFAP immunofluorescence in
non-diabetic and diabetic retinas. The following abbreviations are
used in the figure: outer nuclear layer (ONL); inner nuclear layer
(INL); and ganglion cell layer (GCL). The bar represents 20 μm.
consequence of retinal neurodegeneration. However, given
that CST has neuroprotective and antiapoptotic properties
[7,28,29] it is possible that its lower expression could be
involved in diabetic retinal neurodegeneration.
Finally, the high expression of CST observed in RPE cells
deserves a further comment. In the retina, various ion and
water transport systems are located at the apical side of RPE
adjacent to the subretinal space and, indeed, a high expression
of SST receptor 2 has been shown on this apical membrane of
RPE [30]. We have recently show lower levels of SST in the
vitreous from diabetic patients with macular edema [3]. This
finding suggest that the lower production of SST might be
involved  in  the  pathogenesis  of  diabetic  macular  edema.
Given  that  CST  and  SST  share  the  same  receptors,  it  is
possible that CST (as occurs with SST) participates in the
balance of fluid and ion transport through the retina. However,
specific studies aimed at evaluating the potential role of CST
in the pathogenesis of diabetic macular edema are needed.
In conclusion, we provide evidence that CST is expressed
in the human retina. In addition, an early reduction of CST
expression exists in the retinas of diabetic patients. Since CST
has antiangiogenic, neuroprotective, and anti-inflammatory
effects, our results point to lowered CST expression as a
mechanism  involved  in  the  pathogenesis  of  diabetic
retinopathy. Further studies are needed to elucidate not only
the  precise  role  of  CST  in  the  development  of  diabetic
retinopathy but also its potential role as a therapeutic target.
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